These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 22042366

  • 1. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
    Pritchard KI, Munro A, O'Malley FP, Tu D, Li X, Levine MN, Shepherd L, Chia S, Bartlett JM.
    Breast Cancer Res Treat; 2012 Jan; 131(2):541-51. PubMed ID: 22042366
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [Abstract] [Full Text] [Related]

  • 4. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
    Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO.
    Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7483-90. PubMed ID: 16234514
    [Abstract] [Full Text] [Related]

  • 7. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2/TOP2A Meta-analysis Study Group.
    Lancet Oncol; 2011 Nov 20; 12(12):1134-42. PubMed ID: 21917518
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.
    BMC Cancer; 2013 Mar 28; 13():163. PubMed ID: 23537287
    [Abstract] [Full Text] [Related]

  • 10. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
    Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI.
    J Clin Oncol; 2015 May 20; 33(15):1680-7. PubMed ID: 25897160
    [Abstract] [Full Text] [Related]

  • 11. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May 20; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
    Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, Mouridsen HT.
    Acta Oncol; 2008 May 20; 47(4):725-34. PubMed ID: 18465341
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.
    J Natl Cancer Inst; 2009 May 06; 101(9):644-50. PubMed ID: 19401546
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
    Schildhaus HU, Schroeder L, Merkelbach-Bruse S, Binot E, Büttner R, Kuhn W, Rudlowski C.
    Breast; 2013 Dec 06; 22(6):1066-71. PubMed ID: 24080492
    [Abstract] [Full Text] [Related]

  • 17. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.
    Hum Pathol; 2012 Sep 06; 43(9):1363-75. PubMed ID: 22204715
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 19. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
    Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ.
    Lancet Oncol; 2010 Mar 01; 11(3):266-74. PubMed ID: 20079691
    [Abstract] [Full Text] [Related]

  • 20. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
    Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO.
    Clin Cancer Res; 2012 Apr 15; 18(8):2402-12. PubMed ID: 22351696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.